Are autoantibodies active players or epiphenomena?
- PMID: 9608322
- DOI: 10.1097/00002281-199805000-00008
Are autoantibodies active players or epiphenomena?
Abstract
Autoantibodies have the potential of pathogenicity in several diseases. In rheumatoid arthritis (RA), however, this has not been ultimately proven. RA is characterized by a variety of autoantibodies. Newer insights into characteristics of rheumatoid factors indirectly suggest their pathogenetic involvement. In contrast, antibodies to collagen, despite the availability of an experimental model, do not appear to be pathogenetic in man. Anti-hnRNP antibodies, particularly anti-A2/RA33, are present in RA and experimental models of RA, and therefore, aside from their diagnostic value in established and early RA, could also be involved in the disease process. The nature of Sa, another target antigen in RA, has not yet been elucidated. Filaggrin is the antigen recognized by antikeratin antibodies and antiperinuclear factor; however, citrullin is the target amino acid in filaggrin, and anticitrullin antibodies have a high predictive value. Among a series of cartilage proteins, most have not yet been characterized sufficiently; one, gp39, appears to be of particular interest. Whether or not these antibodies are involved in RA pathogenesis is not yet known. It can be speculated that autoimmunity to some, if not all, of these autoantigens mirrors events important in the development of RA, but further studies on T-cell reactivities and in experimental models are needed to fully understand the involvement.
Similar articles
-
The concurrence of rheumatoid arthritis and limited systemic sclerosis: clinical and serologic characteristics of an overlap syndrome.Arthritis Rheum. 1998 Nov;41(11):1938-45. doi: 10.1002/1529-0131(199811)41:11<1938::AID-ART7>3.0.CO;2-X. Arthritis Rheum. 1998. PMID: 9811047
-
Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor.Br J Rheumatol. 1996 Jul;35(7):620-4. doi: 10.1093/rheumatology/35.7.620. Br J Rheumatol. 1996. PMID: 8670593
-
Autoantibody and metalloproteinase activity in early arthritis.Clin Rheumatol. 2019 Mar;38(3):827-834. doi: 10.1007/s10067-018-4326-5. Epub 2018 Nov 7. Clin Rheumatol. 2019. PMID: 30406565
-
Autoantibodies in rheumatoid arthritis and their clinical significance.Arthritis Res. 2002;4 Suppl 2(Suppl 2):S1-5. doi: 10.1186/ar551. Epub 2002 Apr 26. Arthritis Res. 2002. PMID: 12110150 Free PMC article. Review.
-
[Novel autoantibodies and their target antigens in rheumatoid arthritis].Nihon Rinsho. 2002 Dec;60(12):2263-8. Nihon Rinsho. 2002. PMID: 12510348 Review. Japanese.
Cited by
-
B cells in rheumatoid arthritis.Arthritis Res. 2000;2(2):126-31. doi: 10.1186/ar77. Epub 2000 Feb 24. Arthritis Res. 2000. PMID: 11094422 Free PMC article. Review.
-
A revival of the B cell paradigm for rheumatoid arthritis pathogenesis?Arthritis Res. 2000;2(2):90-4. doi: 10.1186/ar73. Epub 2000 Feb 24. Arthritis Res. 2000. PMID: 11094418 Free PMC article. Review.
-
Therapy of systemic lupus erythematosus: a look into the future.Arthritis Res. 2002;4 Suppl 3(Suppl 3):S25-30. doi: 10.1186/ar579. Epub 2002 May 9. Arthritis Res. 2002. PMID: 12110120 Free PMC article. Review.
-
Innate immunity as a hired gun: but is it rheumatoid arthritis?J Exp Med. 2002 Apr 15;195(8):F33-5. doi: 10.1084/jem.20020389. J Exp Med. 2002. PMID: 11956300 Free PMC article. No abstract available.
-
Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value.Arthritis Res. 2002;4(2):87-93. doi: 10.1186/ar395. Epub 2001 Nov 6. Arthritis Res. 2002. PMID: 11879544 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical